Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

High prevalence of hepatitis C virus infection among incarcerated persons: Results from the Louisiana Hepatitis C Elimination Plan's opt-out testing program in prisons.

Author information

Affiliations

  • 1. Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
      Authors
    • Irvin R 1
    • Manogue S 1
    • Thomas DL 1
    (3 authors)
  • 2. Ochsner Health System, New Orleans, Louisiana, USA.
      Authors
    • Landry G 2, 4
    (1 author)
  • 3. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
      Authors
    • Jones MR 3
    • Sugarman OK 3
    • Mehta SH 3
    (3 authors)
  • 4. Louisiana Department of Health, Office of Public Health, New Orleans, Louisiana, USA.
      Authors
    • Landry G 2, 4
    • James A 4
    • Schexnayder J 4
    • Wendell D 4
    • Barthe K 4
    • Britton E 4
    • LeSar K 4
    • Brown C 4
    • Burgess S 4
    • Robinson W 4
    (10 authors)
  • 5. Louisiana Department of Public Safety and Corrections, Baton Rouge, Louisiana, USA.
      Authors
    • Rodriguez S 5
    (1 author)

ORCIDs linked to this article

Journal of Viral Hepatitis, 17 May 2024, 31(7):432-435
https://doi.org/10.1111/jvh.13941 PMID: 38758571 

Free full text available after 01 Jul 2025

Abstract 

In the United States, modelling studies suggest a high prevalence of hepatitis C virus (HCV) infection in incarcerated populations. However, limited HCV testing has been conducted in prisons. Through the Louisiana Hepatitis C Elimination Plan, persons incarcerated in the eight state prisons were offered HCV testing from 20 September 2019 to 14 July 2022, and facility entry/exit HCV testing was introduced. Multivariable logistic regression was used to evaluate associations with HCV antibody (anti-HCV) positivity and viremia. Of 17,231 persons in the eight state prisons screened for anti-HCV, 95.1% were male, 66.7% were 30-57 years old, 3% were living with HIV, 68.2% were Black and 2904 (16.9%) were anti-HCV positive. HCV RNA was detected in 69.3% of anti-HCV positive individuals tested. In the multivariable model, anti-HCV positivity was associated with older age including those 30-57 (odds ratio [OR] 3.53, 95% confidence interval [CI] 2.96-4.20) and those ≥58 (OR 10.43, 95% CI 8.66-12.55) as compared to those ≤29 years of age, living with HIV (OR 1.68, 95% CI 1.36-2.07), hepatitis B (OR 1.83, 95% CI 1.25-2.69) and syphilis (OR 1.51, 95% CI 1.23-1.86). HCV viremia was associated with male sex (OR 1.89, 95% CI 1.36-2.63) and Black race (OR 1.42, 95% CI 1.20-1.68). HCV prevalence was high in the state prisons in Louisiana compared to community estimates. To the extent that Louisiana is representative, to eliminate HCV in the United States, it will be important for incarcerated persons to have access to HCV testing and treatment.

Full text links 

Read article at publisher's site: https://doi.org/10.1111/jvh.13941

References 

Articles referenced by this article (6)

Citations & impact 

This article has not been cited yet.

Impact metrics

Alternative metrics

Altmetric item for https://www.altmetric.com/details/163441884
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/163441884

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Gilead Sciences

    NIAID NIH HHS (1)

    NIDA NIH HHS (2)

    National Institute of Allergy and Infectious Diseases (1)

    National Institute on Drug Abuse (1)